164 related articles for article (PubMed ID: 29329823)
21. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
22. Effect of early conversion to everolimus together with prophylaxis with valganciclovir in the prevention of cytomegalovirus infection in heart transplant recipients.
Díaz Molina B; Velasco Alonso E; Lambert Rodríguez JL; Rodríguez Bernardo MJ; Rozado Castaño J; Padrón Encalada R; Martín Fernández M; Pun Chinchai F; Colunga Blanco S; García Campos A
Transplant Proc; 2015; 47(1):130-1. PubMed ID: 25645790
[TBL] [Abstract][Full Text] [Related]
23. Multiple 'doughnut' granulomas in a liver transplant patient with CMV reactivation.
Dejhansathit S; Miller AM; Suvannasankha A
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30580302
[No Abstract] [Full Text] [Related]
24. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
Asberg A; Rollag H; Hartmann A
Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
[TBL] [Abstract][Full Text] [Related]
25. [Pneumonia in immunocompromised patients].
Mayaud C; Fartoukh M; Parrot A
Rev Prat; 2003 Nov; 53(18):1983-8. PubMed ID: 15008209
[TBL] [Abstract][Full Text] [Related]
26. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
27. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
Grossi P; Mohacsi P; Szabolcs Z; Potena L
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
[TBL] [Abstract][Full Text] [Related]
29. DHPG (Gancyclovir) improves survival in CMV pneumonia.
Mai M; Nery J; Sutker W; Husberg B; Klintmalm G; Gonwa T
Transplant Proc; 1989 Feb; 21(1 Pt 2):2263-5. PubMed ID: 2540565
[No Abstract] [Full Text] [Related]
30. Rapid detection cytomegalovirus pneumonia in recipients of bone marrow transplant: evaluation and comparison of five survey methods for bronchoalveolar lavage fluid.
Goto H; Yuasa K; Sakamaki H; Nakata K; Komuro I; Iguchi M; Okamura T; Ieki R; Tanikawa S; Akiyama H; Onozawa Y; Mochida Y
Bone Marrow Transplant; 1996 May; 17(5):855-60. PubMed ID: 8733709
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy.
Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Prenner G
Scand J Infect Dis Suppl; 1995; 99():100-3. PubMed ID: 8668929
[TBL] [Abstract][Full Text] [Related]
32. CMV disease complicating induction immunosuppressive treatment for ANCA-associated vasculitis.
Tollitt J; O'Riordan E; Poulikakos D
BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26907821
[TBL] [Abstract][Full Text] [Related]
33. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
35. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.
Brum S; Nolasco F; Sousa J; Ferreira A; Possante M; Pinto JR; Barroso E; Santos JR
Transplant Proc; 2008 Apr; 40(3):752-4. PubMed ID: 18455007
[TBL] [Abstract][Full Text] [Related]
36. Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation?
Rodríguez-Serrano M; Sánchez-Lázaro I; Almenar-Bonet L; Martínez-Dolz L; Portolés-Sanz M; Rivera-Otero M; Salvador-Sanz A
Clin Transplant; 2014 Jan; 28(1):88-95. PubMed ID: 24325305
[TBL] [Abstract][Full Text] [Related]
37. A case of late-onset cytomegalovirus myocarditis in an orthotopic heart transplant recipient; case report and review of the literature.
Mylvaganam R; Glaser A; Moss N; Rana M
Diagn Microbiol Infect Dis; 2018 Jun; 91(2):153-155. PubMed ID: 29459054
[TBL] [Abstract][Full Text] [Related]
38. Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
Deback C; Burrel S; Varnous S; Carcelain G; Conan F; Aït-Arkoub Z; Autran B; Gandjbakhch I; Agut H; Boutolleau D
Antivir Ther; 2015; 20(2):249-54. PubMed ID: 25219330
[TBL] [Abstract][Full Text] [Related]
39. [The significance of cytomegalovirus infection in the period after a heart transplant].
Manito N; Pérez JL; Roca J; Niubó J; Gausí C; Castells E
Rev Esp Cardiol; 1995; 48 Suppl 7():108-14. PubMed ID: 8775825
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
